Alkermes plc (ALKS)
|Net Income (ttm)||-129.14M|
|Day's Range||28.53 - 29.04|
|52-Week Range||21.75 - 32.79|
|Price Target||32.03 (+11.84%)|
|Earnings Date||Feb 15, 2023|
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia a... [Read more]
In 2021, Alkermes's revenue was $1.17 billion, an increase of 13.00% compared to the previous year's $1.04 billion. Losses were -$48.17 million, -56.55% less than in 2020.Financial Statements
According to 16 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $32.03, which is an increase of 11.84% from the latest price.
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK — DUBLIN , Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that...
DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. ...
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
DUBLIN , Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference o...
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday,...
DUBLIN , Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022...
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
— Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0. 02...
— Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business — — Separation Expected to Unlock Value Through Sharpened Strategic Focus, Simplified Capital Allocation D...
– 6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Oct. 27, 2022 /PRNewswi...
DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
PEARL RIVER, N.Y.
-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq:...
̶ Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ̶ DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the pres...
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.
Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...
Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...
Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada.
Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
— Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales — — GAAP Loss per Share of $0.18 and Non-GAAP Earnings per Share of $0. 06 — — Raises Financial Expe...